Azitra, Inc. (AZTR)
After hours:
| Previous close | 0.2201 |
| Open | 0.2174 |
| Bid | 0.2100 x 1200 |
| Ask | 0.2185 x 800 |
| Day's range | 0.2100 - 0.2283 |
| 52-week range | 0.1610 - 5.1800 |
| Volume | |
| Avg. volume | 668,755 |
| Market cap | 6.294M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.50 |
- Business Wire
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting
BRANFORD, Conn., April 22, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company’s platform and pipeline. The data will be presented on Friday, May 10, 2024, in two oral sessions entitled "Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases" and "Staphylococcus epidermidis Strain Expressing LEKTI-D6 (ATR12
- Business Wire
Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024
BRANFORD, Conn., April 18, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover treatments for serious skin diseases at three upcoming scientific and medical conferences:
- Business Wire
Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
BRANFORD, Conn., March 15, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update.
